OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
Silvia Márquez-Megías, Ricardo Nalda‐Molina, Javier Sanz‐Valero, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1009-1009
Open Access | Times Cited: 26
Silvia Márquez-Megías, Ricardo Nalda‐Molina, Javier Sanz‐Valero, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1009-1009
Open Access | Times Cited: 26
Showing 1-25 of 26 citing articles:
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
Hannah Gordon, Silvia Minozzi, Uri Kopylov, et al.
Journal of Crohn s and Colitis (2024)
Open Access | Times Cited: 49
Understanding the therapeutic toolkit for inflammatory bowel disease
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Sophie Vieujean, Vipul Jairath, Laurent Peyrin‐Biroulet, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access | Times Cited: 2
Laboratory Tests in Inflammatory Bowel Disease: An Evidence-Based Approach to Daily Practice
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
Katelin Durham, Tyler Atagozli, David E. Elliott, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 491-491
Open Access
Reversing the Inflammatory Process—25 Years of Tumor Necrosis Factor-α Inhibitors
Katharina Muth, Jürgen Rech, Florian Losch, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 5039-5039
Open Access | Times Cited: 13
Katharina Muth, Jürgen Rech, Florian Losch, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 5039-5039
Open Access | Times Cited: 13
Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Konstantinos Papamichael, Gabriele Stocco, Ainhoa Ruiz del Agua
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 5, pp. 579-590
Open Access | Times Cited: 10
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab
Rachel Porth, Tina Deyhim, Samantha Zullow, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 3
Rachel Porth, Tina Deyhim, Samantha Zullow, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 3
Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
Liang‐Fang Wang, Pingrun Chen, Si-Ke He, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 29, pp. 4481-4498
Open Access | Times Cited: 9
Liang‐Fang Wang, Pingrun Chen, Si-Ke He, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 29, pp. 4481-4498
Open Access | Times Cited: 9
The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape
Sanjay K. Murthy, Adam V. Weizman, M Ellen Kuenzig, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 6, Iss. Supplement_2, pp. S97-S110
Open Access | Times Cited: 5
Sanjay K. Murthy, Adam V. Weizman, M Ellen Kuenzig, et al.
Journal of the Canadian Association of Gastroenterology (2023) Vol. 6, Iss. Supplement_2, pp. S97-S110
Open Access | Times Cited: 5
A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination Therapy
Sanket Patel, Andrés Yarur
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6577-6577
Open Access | Times Cited: 5
Sanket Patel, Andrés Yarur
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6577-6577
Open Access | Times Cited: 5
90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients
Pasqua Letizia Pesole, Marina Liso, Rossella Donghia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3955-3955
Open Access | Times Cited: 4
Pasqua Letizia Pesole, Marina Liso, Rossella Donghia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3955-3955
Open Access | Times Cited: 4
Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus
Sandro Ardizzone, Alessandro Armuzzi, Flavio Caprioli, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 1, pp. 98-105
Open Access | Times Cited: 4
Sandro Ardizzone, Alessandro Armuzzi, Flavio Caprioli, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 1, pp. 98-105
Open Access | Times Cited: 4
Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease
Tal Marshanski, Eliana Fanous, Noa Tal, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 79, Iss. 3, pp. 564-572
Closed Access | Times Cited: 1
Tal Marshanski, Eliana Fanous, Noa Tal, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 79, Iss. 3, pp. 564-572
Closed Access | Times Cited: 1
Proactive therapeutic drug monitoring of biologic drugs in patients with inflammatory bowel disease, inflammatory arthritis, and psoriasis: systematic review and meta-analysis
Dena Zeraatkar, Tyler Pitre, Sarah Kirsh, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e000998-e000998
Open Access | Times Cited: 1
Dena Zeraatkar, Tyler Pitre, Sarah Kirsh, et al.
BMJ Medicine (2024) Vol. 3, Iss. 1, pp. e000998-e000998
Open Access | Times Cited: 1
Impact of proactive of infliximab monitoring using the Bayesian approach in the maintenance phase in patients with inflammatory bowel disease
Lidia Díaz, Carles Iniesta Navalón, Rosa Gómez Espín, et al.
Gastroenterología y Hepatología (2022) Vol. 46, Iss. 7, pp. 504-511
Closed Access | Times Cited: 5
Lidia Díaz, Carles Iniesta Navalón, Rosa Gómez Espín, et al.
Gastroenterología y Hepatología (2022) Vol. 46, Iss. 7, pp. 504-511
Closed Access | Times Cited: 5
Therapeutic Drug Monitoring (TDM) Implementation in Public Hospitals in Greece in 2003 and 2021: A Comparative Analysis of TDM Evolution over the Years
Gavriela Voulgaridou, Theodora Paraskeva, Georgia Ragia, et al.
Pharmaceutics (2023) Vol. 15, Iss. 9, pp. 2181-2181
Open Access | Times Cited: 2
Gavriela Voulgaridou, Theodora Paraskeva, Georgia Ragia, et al.
Pharmaceutics (2023) Vol. 15, Iss. 9, pp. 2181-2181
Open Access | Times Cited: 2
Four‐year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing
Paula Keating, Barry D. Hock, Stewart M. Smith, et al.
Internal Medicine Journal (2023) Vol. 53, Iss. 11, pp. 2123-2127
Open Access | Times Cited: 2
Paula Keating, Barry D. Hock, Stewart M. Smith, et al.
Internal Medicine Journal (2023) Vol. 53, Iss. 11, pp. 2123-2127
Open Access | Times Cited: 2
Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease
Jessica C. Petrov, Sean Fine, Raneem Alzahrani, et al.
Journal of Clinical Gastroenterology (2024) Vol. 59, Iss. 1, pp. 77-81
Closed Access
Jessica C. Petrov, Sean Fine, Raneem Alzahrani, et al.
Journal of Clinical Gastroenterology (2024) Vol. 59, Iss. 1, pp. 77-81
Closed Access
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East
Gaurav Nigam, Kelly Chatten, Ala I. Sharara, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access
Gaurav Nigam, Kelly Chatten, Ala I. Sharara, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access
The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
Junya Song, Huihui Zhang, Huihua Zhang, et al.
Pediatric Discovery (2024)
Open Access
Junya Song, Huihui Zhang, Huihua Zhang, et al.
Pediatric Discovery (2024)
Open Access
Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis
Yang Hu, Zaiwei Song, Yuan Gao, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 10, pp. 935-948
Open Access
Yang Hu, Zaiwei Song, Yuan Gao, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 10, pp. 935-948
Open Access
State of the art of real-life concentration monitoring of rifampicin and its implementation contextualized in resource-limited settings: the Tanzanian case
Yuan J Pétermann, Bibie Said, Annie E Cathignol, et al.
JAC-Antimicrobial Resistance (2024) Vol. 6, Iss. 6
Open Access
Yuan J Pétermann, Bibie Said, Annie E Cathignol, et al.
JAC-Antimicrobial Resistance (2024) Vol. 6, Iss. 6
Open Access
Optimization of a Quantitative Anti-Drug Antibodies against Infliximab Assay with the Liquid Chromatography-Tandem Mass Spectrometry: A Method Validation Study and Future Perspectives
E. H. Smeijsters, Kim C. M. van der Elst, Amy Visch, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1477-1477
Open Access | Times Cited: 1
E. H. Smeijsters, Kim C. M. van der Elst, Amy Visch, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1477-1477
Open Access | Times Cited: 1
Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Anam Fahad, Somia Jamal Sheikh, Mishaal Munir, et al.
IntechOpen eBooks (2023)
Open Access | Times Cited: 1
Anam Fahad, Somia Jamal Sheikh, Mishaal Munir, et al.
IntechOpen eBooks (2023)
Open Access | Times Cited: 1
Cost-effectiveness of therapeutic drug monitoring (TDM) of biologic treatment in rheumatic diseases: a narrative review
Konstantin Tachkov, Petya Nikolova, Rumyana Simeonova, et al.
Biotechnology & Biotechnological Equipment (2023) Vol. 37, Iss. 1
Open Access | Times Cited: 1
Konstantin Tachkov, Petya Nikolova, Rumyana Simeonova, et al.
Biotechnology & Biotechnological Equipment (2023) Vol. 37, Iss. 1
Open Access | Times Cited: 1
Inflammatory Bowel Disease - Principles and Practice [Working Title]
IntechOpen eBooks (2023)
Closed Access
IntechOpen eBooks (2023)
Closed Access
